Cited by 152Glaucoma and retinal disordersDrug-Induced Ocular ToxicityBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP

Brandt, James D, VanDenburgh, Amanda M, Chen, Kuankuan, Whitcup, Scott M·2001·Ophthalmology

Open this paper in CoChat — free account

Abstract

Objective To compare the safety, tolerability, and efficacy of bimatoprost 0.03% instilled once daily or twice daily with timolol 0.5% twice daily. Design Multicenter, 3-month, randomized, double-masked, interventional comparison trial. Participants Patients diagnosed with ocular hypertension or glaucoma (n = 596). Intervention Patients received bimatoprost 0.03% ophthalmic solution once daily (8 PM, with vehicle control at 8 AM), bimatoprost 0.03% twice daily (8 AM; 8 PM), or timolol 0.5% twice daily (8 AM; 8 PM) in an uneven 2:2:1 randomization. Scheduled visits were at prestudy, baseline (day 0), weeks 2 and 6, and month 3. Intraocular pressure (IOP) was measured at 8 AM (predose), 10 AM, and 4 PM. Main outcome measures The primary outcome measure was reduction in IOP in the eye with higher IOP at baseline. Secondary outcome measures included safety variables (adverse events, ophthalmoscopy, biomicroscopy, iris pigmentation, laser-flare meter, visual acuity, visual fields, heart rate, blood pressure, blood chemistry, hematology, and urinalysis). Results At month 3, the mean reduction in IOP from baseline at 8 AM was 9.16 mmHg (35.2%) with bimatoprost once daily, 7.78 mmHg (30.4%) with bimatoprost twice daily, and 6.74 mmHg (26.2%) with timolol twice daily. At all follow-up visits, mean IOP reductions were significantly greater in the bimatoprost once daily group than in the timolol group at each time point (8 AM, 10 AM, and 4 PM; P < 0.001). Twice-daily dosing of bimatoprost also provided significantly greater mean reductions in IOP than timolol at most time points but was not as effective as once-daily dosing. Bimatoprost was associated with significantly more hyperemia and eyelash growth than timolol, whereas timolol was associated with significantly more burning and stinging sensation in eyes. Overall, bimatoprost was well tolerated with few discontinuations because of adverse events. Conclusions Bimatoprost 0.03% once daily was safe and statistically superior to timolol 0.5% twice daily in lowering IOP in patients with ocular hypertension or glaucoma. Bimatoprost given once daily consistently provided IOP reductions approximately 2 to 3 mmHg greater than those provided by timolol. Once-daily dosing of bimatoprost, 0.03%, demonstrated greater IOP-lowering effect and better ocular tolerability than twice-daily dosing.

Integrity signals

Registry

Crossref · 10.1016/s0161-6420(01)00584-x

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical Methods for Rates and Proportions.
Everitt, B. S., & Fleiss, J. L. (1981) · Biometrics · doi:10.2307/2530193 · Cited by 9,034
Rank transformations as a bridge between parametric and nonparametric statistics
Conover, W. J., & Iman, R. L. (1981) · The American Statistician · doi:10.1080/00031305.1981.10479327 · Cited by 3,922
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,756
Nonparametrics: Statistical Methods Based on Ranks
Mergenthaler, M. J., & Lehmann, E. L. (1979) · Technometrics · doi:10.2307/1268531 · Cited by 3,353
Nonparametrics: Statistical Methods Based on Ranks.
Beaver, R. J., & Lehmann, E. L. (1976) · Biometrics · doi:10.2307/2529529 · Cited by 2,067
Effects on Intraocular Pressure and Side Effects of 0.005% Latanoprost Applied Once Daily, Evening or Morning
Alm, A., & Stjernschantz, J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30798-1 · Cited by 500
Comparison of Latanoprost and Timolol in Patients with Ocular Hypertension and Glaucoma
Camras, C. B. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30749-5 · Cited by 494
A Six-month, Randomized, Double-masked Study Comparing Latanoprost with Timolol in Open-angle Glaucoma and Ocular Hypertension
Watson, P. G., & Stjernschantz, J. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30750-1 · Cited by 449
Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2
Yu, M., Ives, D., & Ramesha, C. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21181 · Cited by 407
Why Do Some People Go Blind from Glaucoma?
Grant, W. M., & Burke, J. F. (1982) · Ophthalmology · doi:10.1016/s0161-6420(82)34675-8 · Cited by 390

Show all 24 references

Research works printed but not linked: 1

Kass, 1989, Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension, Trans Am Ophthalmol Soc, 87, 598

Sorted by citations

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure:
Parrish, R. K., II, Palmberg, P. F., & Sheu, W.-P. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(03)00098-9 · Cited by 473
Intraocular Pressure–Lowering Effects of All Commonly Used Glaucoma Drugs
van der Valk, R., Webers, C. A. B., Schouten, J., Zeegers, M. P., Hendrikse, F., & Prins, M. H. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.01.042 · Cited by 448
A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
Noecker, R. S., Dirks, M. S., Choplin, N. T., Bernstein, P., Batoosingh, A. L., & Whitcup, S. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01827-5 · Cited by 319
Self-citation
The Pharmacology of Bimatoprost (Lumigan™)
Woodward, D. F., Krauss, A. H. ‐., Chen, J., LAI, R. K., Spada, C. S., Burk, R. M., Andrews, S. W., Shi, L., Liang, Y., Kedzie, K. M., et al. (2001) · Survey of Ophthalmology · doi:10.1016/s0039-6257(01)00224-7 · Cited by 221
One-Year, Randomized Study Comparing Bimatoprost and Timolol in Glaucoma and Ocular Hypertension
Higginbotham, E. J. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1286 · Cited by 199
Six-Month Comparison of Bimatoprost Once-Daily and Twice-Daily with Timolol Twice-Daily in Patients with Elevated Intraocular Pressure
Sherwood, M., & Brandt, J. (2001) · Survey of Ophthalmology · doi:10.1016/s0039-6257(01)00219-3 · Cited by 197
Self-citation
Development of specific Rho-kinase inhibitors and their clinical application
Tamura, M., Nakao, H., Yoshizaki, H., Shiratsuchi, M., Shigyo, H., Yamada, H., Ozawa, T., Totsuka, J., & Hidaka, H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.06.015 · Cited by 178
The side effects of the prostaglandin analogues
Holló, G. (2006) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.1.45 · Cited by 165
Barriers to Glaucoma Drug Delivery
Ghate, D. A., & Edelhauser, H. F. (2008) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31814b990d · Cited by 148
Efficacy and Tolerability of Prostaglandin Analogs
Aptel, F., Cucherat, M., & Denis, P. (2008) · Journal of Glaucoma · doi:10.1097/ijg.0b013e3181666557 · Cited by 130
Six-Month Intraocular Pressure Reduction with a Topical Bimatoprost Ocular Insert
Brandt, J. D., Sall, K. N., Dubiner, H. B., Benza, R., Alster, Y., Walker, G. A., Semba, C. P., Budenz, D. L., Day, D. G., Flowers, B. E., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.026 · Cited by 116
Self-citation
Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost
Gandolfi, S., & Cimino, L. (2003) · Ophthalmology · doi:10.1016/s0161-6420(02)01891-2 · Cited by 111
Bimatoprost and Travoprost
Eisenberg, D., Toris, C. B., & Camras, C. B. (2002) · Survey of Ophthalmology · doi:10.1016/s0039-6257(02)00327-2 · Cited by 109
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Lewis, R. A., Levy, B. L., Ramirez, N., Kopczynski, C., Usner, D. W., Novack, G. D., & for the PG324-CS201 Study Group (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306778 · Cited by 100
Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure
Fellman, R. L., Sullivan, E., Ratliff, M., Silver, L. H., Whitson, J. T., Turner, F. D., Weiner, A. L., & Davis, A. A. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)01010-2 · Cited by 97
Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure
Dubiner, H. B., Sircy, M. D., Landry, T. A., Bergamini, M. V. W., Silver, L. H., Turner, F. D., Robertson, S. M., Andrew, R. M., Weiner, A. L., & Przydryga, J. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90008-2 · Cited by 93
Bimatoprost in the treatment of eyelash hypotrichosis
Law, S. K. (2010) · Clinical ophthalmology · doi:10.2147/opth.s6480 · Cited by 88
Enhancing the Growth of Natural Eyelashes: The Mechanism of Bimatoprost-Induced Eyelash Growth
COHEN, J. L. (2010) · Dermatologic Surgery · doi:10.1111/j.1524-4725.2010.01522.x · Cited by 85
Conjunctival Hyperemia and the Use of Topical Prostaglandins in Glaucoma and Ocular Hypertension
Feldman, R. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803762718088 · Cited by 85
Commercially Available Prostaglandin Analogs for the Reduction of Intraocular Pressure: Similarities and Differences
Bean, G. W., & Camras, C. B. (2008) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.08.012 · Cited by 86
A review of the use of latanoprost for glaucoma since its launch
Digiuni, M., Fogagnolo, P., & Rossetti, L. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.662219 · Cited by 82
Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study
Smith, S., Fagien, S., Whitcup, S. M., Ledon, F., Somogyi, C., Weng, E., & Beddingfield, F. C. (2012) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.005 · Cited by 79
Self-citation
A Double-Masked, Randomized, Parallel Comparison of a Fixed Combination of Bimatoprost 0.03%/Timolol 0.5% with Non-Fixed Combination use in Patients with Glaucoma or Ocular Hypertension
Hommer, A., Ganfort® Investigators Group I, Boone, W. B., Branch, J. D., Brigatti, L., Christie, W. C., Clifford, W. S., Cooke, D. L., Corwin, J., Davitt, W. F., et al. (2007) · European Journal of Ophthalmology · doi:10.1177/112067210701700108 · Cited by 79
Adverse periocular reactions to five types of prostaglandin analogs
Inoue, K., Shiokawa, M., Higa, R., Sugahara, M., Soga, T., Wakakura, M., & Tomita, G. (2012) · Eye · doi:10.1038/eye.2012.195 · Cited by 74
Long-term Safety and Efficacy of a Sustained-Release Bimatoprost Ocular Ring
Brandt, J. D., Dubiner, H. B., Benza, R., Sall, K. N., Walker, G. A., Semba, C. P., Budenz, D. L., Day, D. G., Flowers, B. E., Lee, S. J., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.04.022 · Cited by 71
Self-citation
Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension
Cohen, J. S., Gross, R. L., Cheetham, J. K., VanDenburgh, A. M., Bernstein, P., & Whitcup, S. M. (2004) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2003.12.019 · Cited by 71
Self-citation
Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma
Holmström, S., Buchholz, P., Walt, J. G., Wickstrøm, J., & Aagren, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x65600 · Cited by 70
Patient Persistency with ocular prostaglandin therapy: A population-based, retrospective study
Reardon, G., Schwartz, G. F., & Mozaffari, E. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80074-7 · Cited by 68
Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications
Belamkar, A. V., Harris, A., Zukerman, R. J., Siesky, B. A., Oddone, F., Vercellin, A. C. V., & Ciulla, T. A. (2022) · Annals of Medicine · doi:10.1080/07853890.2021.1955146 · Cited by 67
Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
McCluskey (2010) · Clinical ophthalmology · doi:10.2147/opth.s10441 · Cited by 67
A randomised, double masked, multicentre clinical trial comparing bimatoprost and timolol for the treatment of glaucoma and ocular hypertension
Whitcup, S. M. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.1.57 · Cited by 67
Self-citation
A Double-Masked, Randomized, Parallel Comparison of a Fixed Combination of Bimatoprost 0.03%/Timolol 0.5% with Non-Fixed Combination Use in Patients with Glaucoma or Ocular Hypertension
Robin, A. L. (2007) · European Journal of Ophthalmology · doi:10.1177/112067210701700436 · Cited by 65
The management of glaucoma and intraocular hypertension: current approaches and recent advances
Noecker, R. J. (2006) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2006.2.2.193 · Cited by 63
A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension
Coleman, A. L., Lerner, S. F., Bernstein, P., & Whitcup, S. M. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00662-6 · Cited by 62
Self-citation
Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery
Camras, C. B., Toris, C. B., Sjöquist, B., Milleson, M., Thörngren, J., Hejkal, T. W., Patel, N. R., Barnett, E. M., Smolyak, R., Hasan, S., et al. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2004.06.028 · Cited by 59
Clinical Options for the Reduction of Elevated Intraocular Pressure
Crawley, L. A., Zamir, S. M., Cordeiro, M. F., & Guo, L. (2012) · Ophthalmology and Eye Diseases · doi:10.4137/oed.s4909 · Cited by 57
Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides
Costagliola, C., dell’Omo, R., Romano, M. R., Rinaldi, M., Zeppa, L., & Parmeggiani, F. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903300129 · Cited by 54
Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management
Cantor, L. B. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.4.721 · Cited by 54
Comparative Efficacy and Tolerability of Topical Prostaglandin Analogues for Primary Open-Angle Glaucoma and Ocular Hypertension
Lin, L., Zhao, Y. J., Chew, P., Sng, C. C. A., Wong, H. T., Yip, L. W. L., Wu, T. S., Bautista, D., Teng, M., Khoo, A. L., et al. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014548569 · Cited by 53
Clinical Course of Bimatoprost-Induced Periocular Skin Changes in Caucasians
Doshi, M., Edward, D. P., & Osmanovic, S. S. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.041 · Cited by 51
Effect of different dose schedules of travoprost on intraocular pressure and pupil size in the glaucomatous Beagle
Gelatt, K. N., & MacKay, E. O. (2004) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2004.00326.x · Cited by 50
Topical Bimatoprost
Easthope, S. E., & Perry, C. M. (2002) · Drugs & Aging · doi:10.2165/00002512-200219030-00008 · Cited by 50
Increased periocular pigmentation with ocular hypotensive lipid use in African Americans
Herndon, L. W., Williams, R. D., Wand, M., & Asrani, S. (2003) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)02146-3 · Cited by 47
Enhanced Eyelashes: Prescription and Over-the-Counter Options
Jones, D. (2010) · Aesthetic Plastic Surgery · doi:10.1007/s00266-010-9561-3 · Cited by 44
Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: Results from parallel-group comparison trials
Simmons, S. T., Dirks, M. S., & Noecker, R. J. (2004) · Advances in Therapy · doi:10.1007/bf02850157 · Cited by 44
Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis
Chanasumon, N., Sriphojanart, T., & Suchonwanit, P. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s156467 · Cited by 43
Water-Drinking Test in Patients with Primary Open-Angle Glaucoma While Treated with Different Topical Medications
Vetrugno, M., Sisto, D., Trabucco, T., Balducci, F., Noci, N. D., & Sborgia, C. (2005) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2005.21.250 · Cited by 42
Hypertrichosis of vellus hairs of the malar region after unilateral treatment with bimatoprost
Hart, J., & Shafranov, G. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2003.09.002 · Cited by 40
A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma
Dirks, M. S., Noecker, R. J., Earl, M., Roh, S., Silverstein, S., & Williams, R. D. (2006) · Advances in Therapy · doi:10.1007/bf02850159 · Cited by 39
Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension
Abelson, M. B., Mroz, M., Rosner, S. A., Dirks, M. S., & Hirabayashi, D. R. (2003) · Advances in Therapy · doi:10.1007/bf02850114 · Cited by 39
The Impact of a Nationwide Introduction of New Drugs and a Treatment Protocol for Glaucoma on the Number of Glaucoma Surgeries
van der Valk, R., Schouten, J., Webers, C. A. B., Beckers, H. J. M., van Amelsvoort, L. G. P. M., Schouten, H. J. A., Hendrikse, F., & Prins, M. H. (2005) · Journal of Glaucoma · doi:10.1097/01.ijg.0000159121.11371.5f · Cited by 38
Short- and long-term safety of glaucoma drugs
Schuman, J. S. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.2.181 · Cited by 36
Quantitative analysis of eyelash lengthening following topical latanoprost therapy
Sugimoto, M., Sugimoto, M., & Uji, Y. (2002) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(02)80004-7 · Cited by 36
The Comparative Cardiovascular, Pulmonary, Ocular Blood Flow, and Ocular Hypotensive Effects of Topical Travoprost, Bimatoprost, Brimonidine, and Betaxolol
İnan, Ü. U., Ermiş, S. S., Orman, A., Onrat, E., Yücel, A., Öztürk, F., Asagidag, A., & Çelik, A. (2004) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/1080768041725344 · Cited by 35
Therapeutic uses of prostaglandin F2α analogues in ocular disease and novel synthetic strategies
Dams, I., Wasyluk, J., Prost, M. E., & Kutner, A. (2013) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2013.01.001 · Cited by 35
Current and emerging medical therapies for glaucoma
Tsai, J. C., & Kanner, E. M. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.1.109 · Cited by 35
Cost-Effectiveness of Monotherapy Treatment of Glaucoma and Ocular Hypertension With the Lipid Class of Medications
Noecker, R. J., & Walt, J. G. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.06.030 · Cited by 35
The Safety and Efficacy of Bimatoprost/Timolol Fixed Combination: A 1-year Double-masked, Randomized Parallel Comparison to Its Individual Components in Patients With Glaucoma or Ocular Hypertension
Lewis, R. A., Gross, R. L., Sall, K. N., Schiffman, R. M., Liu, C. C., & Batoosingh, A. L. (2010) · Journal of Glaucoma · doi:10.1097/ijg.0b013e3181bdb586 · Cited by 34
Management of hypotrichosis of the eyelashes: Focus on bimatoprost
Fagien, S. (2010) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s5488 · Cited by 32
A Comparative Study of Bimatoprost and Travoprost: Effect on Intraocular Pressure and Ocular Circulation in Newly Diagnosed Glaucoma Patients
Alagöz, G., Gürel, K., Bayer, A., Serin, D., Çelebi, S., & Kükner, Ş. (2008) · Ophthalmologica · doi:10.1159/000112624 · Cited by 32
Bimatoprost – a review
Patil, A. J., Vajaranant, T. S., & Edward, D. P. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903292649 · Cited by 30
Bimatoprost for Eyelash Growth in Japanese Subjects: Two Multicenter Controlled Studies
Harii, K., Arase, S., Tsuboi, R., Weng, E., Daniels, S., & VanDenburgh, A. (2014) · Aesthetic Plastic Surgery · doi:10.1007/s00266-014-0293-7 · Cited by 29
Self-citation
Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials
Wirta, D., VanDenburgh, Weng, Whitcup, S., Kurstjens, & Beddingfield (2011) · Clinical Ophthalmology · doi:10.2147/opth.s17457 · Cited by 29
Self-citation
Cost Considerations in the Medical Management of Glaucoma in the US
Goldberg, L. D., & Walt, J. G. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624030-00005 · Cited by 28
Glaucoma Medications
Kanner, E. M., & Tsai, J. C. (2006) · Drugs & Aging · doi:10.2165/00002512-200623040-00005 · Cited by 27
Effect of Different Dose Schedules of Bimatoprost on Intraocular Pressure and Pupil Size in the Glaucomatous Beagle
Gelatt, K. N., & MacKay, E. O. (2002) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076802321021072 · Cited by 27
Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement
Woodward, J. A., Haggerty, C. J., Stinnett, S. S., & Williams, Z. Y. (2010) · Journal of Cosmetic Dermatology · doi:10.1111/j.1473-2165.2010.00487.x · Cited by 33
Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%
McCarey, B. E., Kapik, B. M., & Kane, F. E. (2004) · Ophthalmology · doi:10.1016/j.ophtha.2003.11.013 · Cited by 26
Comparing bimatoprost and travoprost in black Americans
Noecker, R. J., Earl, M., Mundorf, T. K., Silverstein, S., & Phillips, M. P. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x148418 · Cited by 25
Advances in glaucoma therapeutics
Pang, I., & Clark, A. F. (2002) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.7.1.141 · Cited by 24
Acquired trichomegaly of the eyelashes and hypertrichosis induced by bimatoprost
Herane, M., & Urbina, F. (2004) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2004.01020.x · Cited by 24
A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients
Manni, G., Centofanti, M., Parravano, M., Oddone, F., & Bucci, M. G. (2004) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-0866-2 · Cited by 24
Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
Mishra, D., Sinha, B. P., & Kumar, M. S. (2014) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2014.28.5.399 · Cited by 23
Bimatoprost
Curran, M. P. (2009) · Drugs & Aging · doi:10.2165/11203210-000000000-00000 · Cited by 23
Effect of Changing From Concomitant Timolol Pilocarpine to Bimatoprost Monotherapy on Ocular Blood Flow and IOP in Primary Chronic Angle Closure Glaucoma
Agarwal, H., Gupta, V., & Sihota, R. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803321637636 · Cited by 23
Patient-Reported Outcomes of Bimatoprost for Eyelash Growth
Fagien, S., Walt, J. G., Carruthers, J., Cox, S. E., Wirta, D., Weng, E., & Beddingfield, F. C. (2013) · Aesthetic Surgery Journal · doi:10.1177/1090820x13495887 · Cited by 22
A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma
How, A. C. S., Kumar, R. S., Chen, Y.-M., Su, D. H., Gao, H., Oen, F. T. S., Ho, C., Seah, S. K. W., & Aung, T. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.144535 · Cited by 22
Design of randomized controlled confirmatory trials using historical control data to augment sample size for concurrent controls
Yuan, J., Liu, J., Zhu, R., Lü, Y., & Palm, Ü. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2018.1559853 · Cited by 22
Effects of antiglaucoma drugs on blood flow of optic nerve heads and related structures
Mayama, C., & Araie, M. (2013) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-012-0220-x · Cited by 21
An update on bimatoprost in glaucoma therapy
Cantor, L. B. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1753 · Cited by 20
Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/timolol maleate 0.5% fixed combination
Akyol, N., Kalkisim, A., Türk, A., Kola, M., & Imamoğlu, H. İ. (2017) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2017.1315128 · Cited by 19
A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Olander, K. W., Sato, M. A., Abrams, M., Jerkins, G. W., Lu, F., Dinh, P. V., Odani‐Kawabata, N., Chabi, A., & Shams, N. K. (2021) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001836 · Cited by 19
A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost
Craven, E. R., Liu, Batoosingh, Schiffman, & Whitcup (2010) · Clinical ophthalmology · doi:10.2147/opth.s14915 · Cited by 18
Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
Shafiee, Bowman, Hou, & Hosseini, K. (2013) · Clinical ophthalmology · doi:10.2147/opth.s48766 · Cited by 18
Fixed-combination Bimatoprost/Brimonidine/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil☆
Belfort, R., Paula, J. S., da Silva, M. J. L., Paolera, M. D., Kim, T., Chen, M. Y., & Goodkin, M. L. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.008 · Cited by 19
Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open‐angle and normal tension glaucoma
Faridi, U. A., Saleh, T. A., Ewings, P., Venkateswaran, M., Cadman, D. H., Samarasinghe, R. A., Vodden, J., & Claridge, K. G. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02305.x · Cited by 18
Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
Inoue, K., Masumoto, M., Wakakura, M., Tomita, G., Noguchi, K., & Inoue, K. (2012) · Clinical ophthalmology · doi:10.2147/opth.s27489 · Cited by 17
Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost
Kaback, M. B., Geanon, J. D., Katz, G. J., Ripkin, D., Przydryga, J., & the START Study Group (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004448 · Cited by 17
A Review of Ocular and Systemic Side Effects in Glaucoma Pharmacotherapy
Li, X., Balas, M., & Mathew, D. J. (2025) · Journal of Clinical & Translational Ophthalmology · doi:10.3390/jcto3010002 · Cited by 16
Intraocular Pressure Effects and Mechanism of Action of Topical Versus Sustained-Release Bimatoprost
Lee, S. S., Almazan, A., Decker, S., Zhong, Y., Ghebremeskel, A. N., Hughes, P. M., Robinson, M. R., Burke, J. A., & Weinreb, R. N. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.1.15 · Cited by 16
Ocular effects of topical 0.03% bimatoprost solution in normotensive feline eyes
Régnier, A., Lemagne, C., Ponchet, A., Cazalot, G., Cordet, D. C., & Gelatt, K. N. (2006) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2005.00435.x · Cited by 15
Reporting of noninferiority and equivalence randomized trials for major prostaglandins: A systematic survey of the ophthalmology literature
Eyawo, O., Lee, C.-W., Rachlis, B., & Mills, E. J. (2008) · Trials · doi:10.1186/1745-6215-9-69 · Cited by 15
The one‐eye trial and fellow eye response to prostaglandin analogues
Dayanır, V., Çakmak, H., & Berkit, I. (2008) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2008.01698.x · Cited by 15
Estimated Comparative Costs of Achieving a 20% Reduction in Intraocular Pressure with Bimatoprost or Latanoprost in Patients with Glaucoma or Ocular Hypertension
Fiscella, R. G., & Walt, J. G. (2006) · Drugs & Aging · doi:10.2165/00002512-200623010-00004 · Cited by 15
Ocular Hypotensive Efficacy of Bimatoprost When Used as a Replacement for Latanoprost in the Treatment of Glaucoma and Ocular Hypertension
Bournias, T. E., Lee, D., Gross, R. L., & Mattox, C. G. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803321908329 · Cited by 15
A Masked, Randomized, Phase 3 Comparison of Triple Fixed-Combination Bimatoprost/Brimonidine/Timolol versus Fixed-Combination Brimonidine/Timolol for Lowering Intraocular Pressure
Hartleben-Matkin, C., Parra, J. C., Batoosingh, A. L., Bernstein, P., & Goodkin, M. L. (2017) · Journal of Ophthalmology · doi:10.1155/2017/4586763 · Cited by 14
Effect of bimatoprost on ocular circulation in patients with open-angle glaucoma or ocular hypertension
Akarsu, C., Yılmaz, S., Taner, P., & Ergin, A. (2004) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-004-0906-y · Cited by 14
Medical Management of Glaucoma
Geringer, C. C., & Imami, N. R. (2008) · International Ophthalmology Clinics · doi:10.1097/iio.0b013e318187e8b5 · Cited by 13
Paradoxical Intraocular Pressure Elevation After Combined Therapy With Latanoprost and Bimatoprost
Herndon, L. W., Asrani, S., Williams, G. H., Challa, P., & Lee, P. P. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.847 · Cited by 13
Bimatoprost
Plosker, G. L., & Keam, S. J. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624030-00010 · Cited by 13

Authors: Brandt, J. D., VanDenburgh, A. M., Chen, K., & Whitcup, S. M.
Affiliations: University of California, Davis (US)
Allergan (United States) (US)
Corresponding author: Brandt, James D
ORCID: Brandt, James D
Whitcup, Scott M
Venue: Ophthalmology
Publisher: Elsevier BV
Published: 2001-06
Volume: 108
Issue: 6
Pages: 1023-1031
ISSN: 0161-6420 (ISSN-L)
DOI: 10.1016/s0161-6420(01)00584-x
OpenAlex: W2138342502
Cited by: 152
References: 24
Citations by year: 2025: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 6 · 2013: 5 · 2012: 4
FWCI: 16.08
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Ophthalmology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: bimatoprost, timolol, intraocular pressure, ocular hypertension, glaucoma, once-daily dosing, twice-daily dosing, beta-blockers, prostamide, hyperemia, eyelash growth, drug safety and tolerability, intraocular pressure reduction, visual acuity, heart rate, blood pressure, adverse events, iris pigmentation
MeSH terms: Bimatoprost, Adult, Amides, Antihypertensive Agents, Cloprostenol, Double-Blind Method, Drug Administration Schedule, Female, Glaucoma, Hemodynamics, Humans, Intraocular Pressure, Lipids, Male, Middle Aged, Ocular Hypertension, Ophthalmic Solutions, Safety, Timolol, Visual Acuity, Visual Fields, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks